Nanexa (NANEXA) investor relations material

Executive summary

• Focused on commercial expansion and increased visibility of PharmaShell technology through international forums and industry publications.

• Advanced licensing negotiations for PharmaShell in obesity and type 2 diabetes markets, with parallel development of long-acting semaglutide depot.

• Ongoing collaborations with Moderna and another major pharmaceutical company, with promising evaluation results and potential for expanded partnerships.

• Strengthened patent portfolio with new grants and applications, extending protection into the mid-2040s.

• Financial position remains strong, with cash runway until Q2 2027 and further strengthening expected from licensing agreements.

Financial highlights

• Q2 2026 turnover: SEK 1,654 thousand (down from SEK 2,705 thousand year-over-year).

• Operating profit (EBIT) for Q2: SEK -13,882 thousand (vs. SEK -5,237 thousand year-over-year).

• Profit after tax for Q2: SEK -14,032 thousand (vs. SEK -5,899 thousand year-over-year).

• Cash and cash equivalents at period end: SEK 52,557 thousand (up from SEK 40,263 thousand year-over-year).

• Earnings per share Q2: SEK -0.07 (vs. SEK -0.04 year-over-year).

Outlook and guidance

• Cash position expected to finance operations until Q2 2027.

• Additional financing will be considered only if terms reflect full company value.

• Active pursuit of revenue from licensing and collaboration agreements to ensure long-term financing.